New flu vaccine for seniors enters safety testing

NCT ID NCT07421037

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Ab&B Bio-tech Co., Ltd.JS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing the safety of a new quadrivalent influenza vaccine with an adjuvant (a booster ingredient) in adults aged 65 and older. Eighty participants will receive either the new vaccine, a standard flu vaccine, or a placebo. The study monitors side effects over 12 months to see if the vaccine is safe for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Quadrivalent subunit influenza vaccine with adjuvant (MF59)
What this could lead to: If successful, this could lead to a safer, more effective flu vaccine for older adults, who are at higher risk of severe flu complications.
What could go wrong: This is an early Phase 1 trial with only 80 participants, focused on safety, not effectiveness. The vaccine may not provide better protection than existing flu shots, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA INFLUENZA VACCINE

Contacts and locations

Locations

Yunxi County Center for Disease Control and Prevention

Shiyan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.